Ixekizumab治疗银屑病:三项双盲对照研究整合疗效分析
该分析整合了UNCOVER-1、2、3三项III期研究12周诱导期数据,比较ixekizumab每2周或每4周方案与安慰剂及依那西普的疗效。
要点
- IXE Q2W组第12周PASI 75、90、100应答率分别接近90%、70%和40%。
- IXE Q2W在所有疗效结局上优于IXE Q4W,且起效迅速。
核心结论
- Ixekizumab两种剂量方案均起效迅速,疗效优于安慰剂和依那西普,且IXE Q2W在治疗前12周结局优于IXE Q4W。
研究设计与样本
- 整合三项III期银屑病研究(UNCOVER-1、2、3)的12周诱导期数据。
- 患者接受IXE Q2W(n=1169)、IXE Q4W(n=1165)、依那西普50mg biweekly(n=740,两项研究)或安慰剂(n=792)。
主要发现
- IXE Q2W组第12周PASI 75、90、100应答率分别接近90%、70%和40%。
- Ixekizumab在体表面积受累百分比和指甲银屑病改善上显著优于安慰剂和依那西普。
- IXE Q2W在所有治疗结局上优于IXE Q4W。
关键数值与推荐
- 共同主要终点:第12周sPGA评分为0或1的患者百分比,以及PASI 75应答率。
- 采用Cochran-Mantel-Haenszel检验按研究分层比较治疗间应答率。
临床怎么用
- 对于中重度银屑病患者,ixekizumab每2周方案在12周内可提供更高PASI 75/90/100应答率。
- ixekizumab在体表面积和指甲银屑病改善方面也优于安慰剂和依那西普。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. OBJECTIVES: This analysis represents an overview of the efficacy outcomes from three phase III psoriasis studies. METHODS: Data were integrated from the 12-week induction period of three studies in which patients received ixekizumab 80 mg every 2 weeks (IXE Q2W; n = 1169) or every 4 weeks (IXE Q4W; n = 1165) after an initial 160-mg dose for both; etanercept (50 mg biweekly; n = 740; two studies) or placebo (n = 792). The coprimary end points were the percentages of patients with response of static Physician's Global Assessment (sPGA; score 0 or 1) and ≥ 75% improvement in baseline Psoriasis Area and Severity Index (PASI 75) at week 12. Response rates were compared between treatments using the Cochran-Mantel-Haenszel test stratified by study. Treatment comparisons with placebo included data from three studies, whereas etanercept comparisons were based on two studies. RESULTS: Ixekizumab treatment was superior to placebo (P < 0·001) and etanercept (P < 0·001) on sPGA (0, 1) and PASI 75, with significant differences in PASI improvement at week 1. With IXE Q2W, at week 12, the frequencies of patients achieving PASI 75, 90 and 100 were nearly 90%, 70% and 40%, respectively. Ixekizumab-treated patients showed significantly greater improvement vs. placebo and etanercept in percentage body surface area involvement and fingernail psoriasis. IXE Q2W was superior to IXE Q4W on all treatment outcomes. CONCLUSIONS: Ixekizumab therapy at both dosing regimens demonstrated rapid onset and superior efficacy to placebo and etanercept, with IXE Q2W providing better outcomes than IXE Q4W during the first 12 weeks of treatment.
引用
- Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018. PMID: 28991370. doi:10.1111/bjd.16050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。